RESUMEN
Nonsense-mediated RNA decay (NMD) is a highly conserved and selective RNA degradation pathway that acts on RNAs terminating their reading frames in specific contexts. NMD is regulated in a tissue-specific and developmentally controlled manner, raising the possibility that it influences developmental events. Indeed, loss or depletion of NMD factors have been shown to disrupt developmental events in organisms spanning the phylogenetic scale. In humans, mutations in the NMD factor gene, UPF3B, cause intellectual disability (ID) and are strongly associated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCZ). Here, we report the generation and characterization of mice harboring a null Upf3b allele. These Upf3b-null mice exhibit deficits in fear-conditioned learning, but not spatial learning. Upf3b-null mice also have a profound defect in prepulse inhibition (PPI), a measure of sensorimotor gating commonly deficient in individuals with SCZ and other brain disorders. Consistent with both their PPI and learning defects, cortical pyramidal neurons from Upf3b-null mice display deficient dendritic spine maturation in vivo. In addition, neural stem cells from Upf3b-null mice have impaired ability to undergo differentiation and require prolonged culture to give rise to functional neurons with electrical activity. RNA sequencing (RNAseq) analysis of the frontal cortex identified UPF3B-regulated RNAs, including direct NMD target transcripts encoding proteins with known functions in neural differentiation, maturation and disease. We suggest Upf3b-null mice serve as a novel model system to decipher cellular and molecular defects underlying ID and neurodevelopmental disorders.
Asunto(s)
Corteza Cerebral/metabolismo , Modelos Animales de Enfermedad , Discapacidades para el Aprendizaje/metabolismo , Neurogénesis/fisiología , Inhibición Prepulso/fisiología , Proteínas de Unión al ARN/metabolismo , Animales , Células Cultivadas , Corteza Cerebral/crecimiento & desarrollo , Corteza Cerebral/patología , Espinas Dendríticas/metabolismo , Espinas Dendríticas/patología , Femenino , Discapacidades para el Aprendizaje/patología , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación , Células-Madre Neurales/metabolismo , Células-Madre Neurales/patología , Trastornos del Neurodesarrollo/metabolismo , Trastornos del Neurodesarrollo/patología , Fenotipo , Células Piramidales/metabolismo , Células Piramidales/patología , Proteínas de Unión al ARN/genética , Distribución Aleatoria , Transcripción GenéticaRESUMEN
Variants in CLCN4, which encodes the chloride/hydrogen ion exchanger CIC-4 prominently expressed in brain, were recently described to cause X-linked intellectual disability and epilepsy. We present detailed phenotypic information on 52 individuals from 16 families with CLCN4-related disorder: 5 affected females and 2 affected males with a de novo variant in CLCN4 (6 individuals previously unreported) and 27 affected males, 3 affected females and 15 asymptomatic female carriers from 9 families with inherited CLCN4 variants (4 families previously unreported). Intellectual disability ranged from borderline to profound. Behavioral and psychiatric disorders were common in both child- and adulthood, and included autistic features, mood disorders, obsessive-compulsive behaviors and hetero- and autoaggression. Epilepsy was common, with severity ranging from epileptic encephalopathy to well-controlled seizures. Several affected individuals showed white matter changes on cerebral neuroimaging and progressive neurological symptoms, including movement disorders and spasticity. Heterozygous females can be as severely affected as males. The variability of symptoms in females is not correlated with the X inactivation pattern studied in their blood. The mutation spectrum includes frameshift, missense and splice site variants and one single-exon deletion. All missense variants were predicted to affect CLCN4's function based on in silico tools and either segregated with the phenotype in the family or were de novo. Pathogenicity of all previously unreported missense variants was further supported by electrophysiological studies in Xenopus laevis oocytes. We compare CLCN4-related disorder with conditions related to dysfunction of other members of the CLC family.
Asunto(s)
Canales de Cloruro/genética , Síndromes Epilépticos/genética , Discapacidad Intelectual/genética , Adolescente , Adulto , Anciano , Animales , Niño , Preescolar , Canales de Cloruro/metabolismo , Epilepsia/genética , Síndromes Epilépticos/fisiopatología , Familia , Femenino , Genes Ligados a X , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Mutación de Línea Germinal , Humanos , Discapacidad Intelectual/metabolismo , Masculino , Persona de Mediana Edad , Mutación , Oocitos , Linaje , Fenotipo , Síndrome , Sustancia Blanca/fisiopatología , Xenopus laevisRESUMEN
Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) maps to the Down syndrome critical region; copy number increase of this gene is thought to have a major role in the neurocognitive deficits associated with Trisomy 21. Truncation of DYRK1A in patients with developmental delay (DD) and autism spectrum disorder (ASD) suggests a different pathology associated with loss-of-function mutations. To understand the phenotypic spectrum associated with DYRK1A mutations, we resequenced the gene in 7162 ASD/DD patients (2446 previously reported) and 2169 unaffected siblings and performed a detailed phenotypic assessment on nine patients. Comparison of our data and published cases with 8696 controls identified a significant enrichment of DYRK1A truncating mutations (P=0.00851) and an excess of de novo mutations (P=2.53 × 10(-10)) among ASD/intellectual disability (ID) patients. Phenotypic comparison of all novel (n=5) and recontacted (n=3) cases with previous case reports, including larger CNV and translocation events (n=7), identified a syndromal disorder among the 15 patients. It was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in infancy, impaired speech, stereotypic behavior, hypertonia and a specific facial gestalt. We conclude that mutations in DYRK1A define a syndromic form of ASD and ID with neurodevelopmental defects consistent with murine and Drosophila knockout models.
Asunto(s)
Trastorno Autístico/genética , Discapacidad Intelectual/genética , Mutación , Fenotipo , Proteínas Serina-Treonina Quinasas/genética , Proteínas Tirosina Quinasas/genética , Adolescente , Adulto , Niño , Preescolar , Estudios de Cohortes , Femenino , Retardo del Crecimiento Fetal/genética , Humanos , Masculino , Microcefalia/genética , Persona de Mediana Edad , Convulsiones Febriles/genética , Hermanos , Trastornos del Habla/genética , Trastorno de Movimiento Estereotipado/genética , Síndrome , Adulto Joven , Quinasas DyrKRESUMEN
We report two families with Brunner syndrome living in one state of Australia. The first family had a predicted protein-truncating variant of monoamine oxidase A (MAOA) (p.S251KfsX2). Affected males had mild intellectual disability (ID), obsessive behaviour, limited friendships and were introverted and placid during clinical interview. The family disclosed episodic explosive aggression after a diagnosis was made. The second family had a missense variant in MAOA (p.R45W). Affected males had borderline-mild ID, attention deficit disorder and limited friendships. One had a history of explosive aggression in childhood and episodic symptoms of flushing, headaches and diarrhoea. Their carrier mother had normal intelligence but similar episodic symptoms. Characteristic biochemical abnormalities included high serum serotonin and urinary metanephrines and low urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Symptomatic individuals in the second family had particularly high serotonin levels, and treatment with a serotonin reuptake inhibitor and dietary modification resulted in reversal of biochemical abnormalities, reduction of 'serotonergic' symptoms and behavioural improvement. Brunner syndrome should be considered as a cause of mild ID with paroxysmal behavioural symptoms. It can be screened for with serum/urine metanephrine and serotonin measurement. Cautious treatment with a serotonin reuptake inhibitor, dietary modifications and avoidance of medications contraindicated in patients on monoamine oxidase inhibitors can improve symptoms.
Asunto(s)
Trastornos Disruptivos, del Control de Impulso y de la Conducta/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Discapacidad Intelectual/genética , Monoaminooxidasa/deficiencia , Agresión , Secuencia de Aminoácidos , Trastornos Disruptivos, del Control de Impulso y de la Conducta/tratamiento farmacológico , Exoma , Genes Ligados a X , Estudios de Asociación Genética , Enfermedades Genéticas Ligadas al Cromosoma X/tratamiento farmacológico , Sitios Genéticos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Discapacidad Intelectual/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Modelos Moleculares , Datos de Secuencia Molecular , Terapia Molecular Dirigida , Monoaminooxidasa/química , Monoaminooxidasa/genética , Linaje , Fenotipo , Conformación Proteica , Alineación de SecuenciaRESUMEN
Cerebral palsy (CP) is a common, clinically heterogeneous group of disorders affecting movement and posture. Its prevalence has changed little in 50 years and the causes remain largely unknown. The genetic contribution to CP causation has been predicted to be ~2%. We performed whole-exome sequencing of 183 cases with CP including both parents (98 cases) or one parent (67 cases) and 18 singleton cases (no parental DNA). We identified and validated 61 de novo protein-altering variants in 43 out of 98 (44%) case-parent trios. Initial prioritization of variants for causality was by mutation type, whether they were known or predicted to be deleterious and whether they occurred in known disease genes whose clinical spectrum overlaps CP. Further, prioritization used two multidimensional frameworks-the Residual Variation Intolerance Score and the Combined Annotation-dependent Depletion score. Ten de novo mutations in three previously identified disease genes (TUBA1A (n=2), SCN8A (n=1) and KDM5C (n=1)) and in six novel candidate CP genes (AGAP1, JHDM1D, MAST1, NAA35, RFX2 and WIPI2) were predicted to be potentially pathogenic for CP. In addition, we identified four predicted pathogenic, hemizygous variants on chromosome X in two known disease genes, L1CAM and PAK3, and in two novel candidate CP genes, CD99L2 and TENM1. In total, 14% of CP cases, by strict criteria, had a potentially disease-causing gene variant. Half were in novel genes. The genetic heterogeneity highlights the complexity of the genetic contribution to CP. Function and pathway studies are required to establish the causative role of these putative pathogenic CP genes.
Asunto(s)
Parálisis Cerebral/genética , Heterogeneidad Genética , Predisposición Genética a la Enfermedad/genética , Adulto , Animales , Estudios de Cohortes , Exoma , Femenino , Biblioteca de Genes , Edad Gestacional , Humanos , Masculino , Mutación , Padres , Análisis de Secuencia de ADNRESUMEN
With the increasing number of paediatric cancer patients and with their prolonged survival, the evidence of a number of serious complications induced by anticancer therapy is rising. Osteonecrosis (ON) of bone is one of these treatment-related effects with a multifactorial pathogenesis. In the past few years, several polymorphisms of candidate genes with possible role in development of this disorder were studied.We summarized potential risk factors leading to increased susceptibility to osteonecrosis of bone development in cancer patients during childhood and to present current knowledge in the field of genetic aspects of this condition (Ref. 86).
Asunto(s)
Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Neoplasias/terapia , Osteonecrosis/genética , Inhibidor 1 de Activador Plasminogénico/genética , Factor A de Crecimiento Endotelial Vascular/genética , Corticoesteroides/efectos adversos , Antineoplásicos/efectos adversos , Catalasa/genética , Niño , Predisposición Genética a la Enfermedad , Enfermedad Injerto contra Huésped/complicaciones , Humanos , Neoplasias/complicaciones , Óxido Nítrico Sintasa/genética , Osteonecrosis/etiología , Radioterapia/efectos adversos , Factores de RiesgoRESUMEN
The nonsense-mediated mRNA decay (NMD) pathway was originally discovered by virtue of its ability to rapidly degrade aberrant mRNAs with premature termination codons. More recently, it was shown that NMD also directly regulates subsets of normal transcripts, suggesting that NMD has roles in normal biological processes. Indeed, several NMD factors have been shown to regulate neurological events (for example, neurogenesis and synaptic plasticity) in numerous vertebrate species. In man, mutations in the NMD factor gene UPF3B, which disrupts a branch of the NMD pathway, cause various forms of intellectual disability (ID). Using Epstein Barr virus-immortalized B cells, also known as lymphoblastoid cell lines (LCLs), from ID patients that have loss-of-function mutations in UPF3B, we investigated the genome-wide consequences of compromised NMD and the role of NMD in neuronal development and function. We found that ~5% of the human transcriptome is impacted in UPF3B patients. The UPF3B paralog, UPF3A, is stabilized in all UPF3B patients, and partially compensates for the loss of UPF3B function. Interestingly, UPF3A protein, but not mRNA, was stabilised in a quantitative manner that inversely correlated with the severity of patients' phenotype. This suggested that the ability to stabilize the UPF3A protein is a crucial modifier of the neurological symptoms due to loss of UPF3B. We also identified ARHGAP24, which encodes a GTPase-activating protein, as a canonical target of NMD, and we provide evidence that deregulation of this gene inhibits axon and dendrite outgrowth and branching. Our results demonstrate that the UPF3B-dependent NMD pathway is a major regulator of the transcriptome and that its targets have important roles in neuronal cells.
Asunto(s)
Perfilación de la Expresión Génica/métodos , Discapacidad Intelectual/genética , Degradación de ARNm Mediada por Codón sin Sentido/genética , Proteínas de Unión al ARN/genética , Encéfalo/crecimiento & desarrollo , Línea Celular , Línea Celular Transformada , Células Cultivadas , Proteínas Activadoras de GTPasa/genética , Expresión Génica/genética , Hipocampo/anatomía & histología , Hipocampo/crecimiento & desarrollo , Humanos , Mutación , Neuronas/citología , Proteínas de Unión al ARN/metabolismo , Transducción de Señal/genéticaRESUMEN
Five folate-sensitive fragile sites have been characterized at the molecular level (FRAXA, FRAXE, FRAXF, FRA16A and FRA11B). Three of them (FRAXA, FRAXE and FRA11B) are associated with clinical problems, and two of the genes (FMR1 in FRAXA and CBL2 in FRA11B) have been identified. All of these fragile sites are associated with (CCG)n/(CGG)n triplet expansions which are hypermethylated beyond a critical size. FRAXE is a rare folate sensitive fragile site only recently recognized. Its cytogenetic expression was found to involve the amplification of a (CCG)n repeat adjacent to a CpG island. Normal alleles vary from 6 to 25 copies. Expansions of greater than 200 copies were found in FRAXE expressing males and their FRAXE associated CpG island was fully methylated. An association of FRAXE expression with concurrent methylation of the CpG island and mild non-specific mental handicap in males has been reported by several groups. We now report the cloning and characterization of a gene (FMR2) adjacent to FRAXE. Elements of FMR2 were initially identified from sequences deleted from a developmentally delayed boy. We correlate loss of FMR2 expression with (CCG)n expansion at FRAXE, demonstrating that this is a gene associated with the CpG island adjacent to FRAXE and contributes for FRAXE-associated mild mental retardation.
Asunto(s)
Síndrome del Cromosoma X Frágil/genética , Discapacidad Intelectual/genética , Proteínas Nucleares , Proteínas/genética , Secuencias Repetitivas de Ácidos Nucleicos , Transactivadores , Secuencia de Aminoácidos , Secuencia de Bases , Encéfalo/metabolismo , Niño , Cromosomas Artificiales de Levadura , Cartilla de ADN , Sondas de ADN , Fosfatos de Dinucleósidos , Exones , Femenino , Feto , Expresión Génica , Biblioteca de Genes , Humanos , Masculino , Datos de Secuencia Molecular , Linaje , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Homología de Secuencia de AminoácidoRESUMEN
Spondyloepiphyseal dysplasia tarda (SEDL; MIM 313400) is an X-linked recessive osteochondrodysplasia that occurs in approximately two of every one million people. This progressive skeletal disorder which manifests in childhood is characterized by disproportionate short stature with short neck and trunk, barrel chest and absence of systemic complications. Distinctive radiological signs are platyspondyly with hump-shaped central and posterior portions, narrow disc spaces, and mild to moderate epiphyseal dysplasia. The latter usually leads to premature secondary osteoarthritis often requiring hip arthroplasty. Obligate female carriers are generally clinically and radiographically indistinguishable from the general population, although some cases have phenotypic changes consistent with expression of the gene defect. The SEDL gene has been localized to Xp22 (refs 8,9) in the approximately 2-Mb interval between DXS16 and DXS987 (ref. 10). Here we confirm and refine this localization to an interval of less than 170 kb by critical recombination events at DXS16 and AFMa124wc1 in two families. In one candidate gene we detected three dinucleotide deletions in three Australian families which effect frameshifts causing premature stop codons. The gene designated SEDL is transcribed as a 2.8-kb transcript in many tissues including fetal cartilage. SEDL encodes a 140 amino acid protein with a putative role in endoplasmic reticulum (ER)-to-Golgi vesicular transport.
Asunto(s)
Proteínas Portadoras/genética , Proteínas de Transporte de Membrana , Osteocondrodisplasias/genética , Cromosoma X , Adolescente , Adulto , Secuencia de Aminoácidos , Secuencia de Bases , Femenino , Ligamiento Genético , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación , Linaje , Homología de Secuencia de Aminoácido , Distribución Tisular , Factores de TranscripciónRESUMEN
ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID). ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations. We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2). Five hundred samples without pA1 or pA2 mutations had the entire ARX ORF screened by single stranded polymorphism conformation (SSCP) and/or denaturing high pressure liquid chromatography (dHPLC) analysis. Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T). Four ultraconserved regions distal to ARX (uc466-469) were also screened in a subset of 94 patients, with three unique nucleotide changes identified in two (uc466, uc467). The subcellular localization of full length ARX proteins was assessed for 11 variants. Protein mislocalization increased as a function of pA2 tract length and phenotypic severity, as has been previously suggested for pA1. Similarly, protein mislocalization of the homeodomain mutations also correlated with clinical severity, suggesting an emerging genotype vs cellular phenotype correlation.
Asunto(s)
Discapacidades del Desarrollo/genética , Pruebas Genéticas/métodos , Proteínas de Homeodominio/genética , Factores de Transcripción/genética , Trastorno Autístico/diagnóstico , Trastorno Autístico/genética , Secuencia de Bases , Niño , Preescolar , Duplicación Cromosómica , Estudios de Cohortes , Secuencia Conservada , Discapacidades del Desarrollo/diagnóstico , Femenino , Estudios de Asociación Genética , Células HEK293 , Proteínas de Homeodominio/metabolismo , Humanos , Lactante , Masculino , Mutación , Tasa de Mutación , Linaje , Polimorfismo Conformacional Retorcido-Simple , Factores de Transcripción/metabolismoRESUMEN
Mutations in the UPF3B gene, which encodes a protein involved in nonsense-mediated mRNA decay, have recently been described in four families with specific (Lujan-Fryns and FG syndromes), nonspecific X-linked mental retardation (XLMR) and autism. To further elucidate the contribution of UPF3B to mental retardation (MR), we screened its coding sequence in 397 families collected by the EuroMRX consortium. We identified one nonsense mutation, c.1081C>T/p.Arg361(*), in a family with nonspecific MR (MRX62) and two amino-acid substitutions in two other, unrelated families with MR and/or autism (c.1136G>A/p.Arg379His and c.1103G>A/p.Arg368Gln). Functional studies using lymphoblastoid cell lines from affected patients revealed that c.1081C>T mutation resulted in UPF3B mRNA degradation and consequent absence of the UPF3B protein. We also studied the subcellular localization of the wild-type and mutated UPF3B proteins in mouse primary hippocampal neurons. We did not detect any obvious difference in the localization between the wild-type UPF3B and the proteins carrying the two missense changes identified. However, we show that UPF3B is widely expressed in neurons and also presents in dendritic spines, which are essential structures for proper neurotransmission and thus learning and memory processes. Our results demonstrate that in addition to Lujan-Fryns and FG syndromes, UPF3B protein truncation mutations can cause also nonspecific XLMR. We also identify comorbidity of MR and autism in another family with UPF3B mutation. The neuronal localization pattern of the UPF3B protein and its function in mRNA surveillance suggests a potential function in the regulation of the expression and degradation of various mRNAs present at the synapse.
Asunto(s)
Trastorno Autístico/genética , Codón sin Sentido/genética , Discapacidad Intelectual/genética , Neuronas/metabolismo , Proteínas de Unión al ARN/genética , Adulto , Sustitución de Aminoácidos/genética , Animales , Trastorno Autístico/complicaciones , Línea Celular , Espinas Dendríticas/metabolismo , Regulación hacia Abajo , Femenino , Hipocampo/metabolismo , Humanos , Discapacidad Intelectual/complicaciones , Masculino , Ratones , Persona de Mediana Edad , Linaje , Estabilidad del ARN , Proteínas de Unión al ARN/metabolismoRESUMEN
Cerebral palsy (CP) is the most common cause of childhood physical disability, with incidence between 1/500 and 1/700 births in the developed world. Despite increasing evidence for a major contribution of genetics to CP aetiology, genetic testing is currently not performed systematically. We assessed the diagnostic rate of genome sequencing (GS) in a clinically unselected cohort of 150 singleton CP patients, with CP confirmed at >4 years of age. Clinical grade GS was performed on the proband and variants were filtered, and classified according to American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP) guidelines. Variants classified as pathogenic or likely pathogenic (P/LP) were further assessed for their contribution to CP. In total, 24.7% of individuals carried a P/LP variant(s) causing or increasing risk of CP, with 4.7% resolved by copy number variant analysis and 20% carrying single nucleotide or indel variants. A further 34.7% carried one or more rare, high impact variants of uncertain significance (VUS) in variation intolerant genes. Variants were identified in a heterogeneous group of genes, including genes associated with hereditary spastic paraplegia, clotting and thrombophilic disorders, small vessel disease, and other neurodevelopmental disorders. Approximately 1/2 of individuals were classified as likely to benefit from changed clinical management as a result of genetic findings. In addition, no significant association between genetic findings and clinical factors was detectable in this cohort, suggesting that systematic sequencing of CP will be required to avoid missed diagnoses.
RESUMEN
A growing body of evidence points to a considerable and heterogeneous genetic aetiology of cerebral palsy (CP). To identify recurrently variant CP genes, we designed a custom gene panel of 112 candidate genes. We tested 366 clinically unselected singleton cases with CP, including 271 cases not previously examined using next-generation sequencing technologies. Overall, 5.2% of the naïve cases (14/271) harboured a genetic variant of clinical significance in a known disease gene, with a further 4.8% of individuals (13/271) having a variant in a candidate gene classified as intolerant to variation. In the aggregate cohort of individuals from this study and our previous genomic investigations, six recurrently hit genes contributed at least 4% of disease burden to CP: COL4A1, TUBA1A, AGAP1, L1CAM, MAOB and KIF1A. Significance of Rare VAriants (SORVA) burden analysis identified four genes with a genome-wide significant burden of variants, AGAP1, ERLIN1, ZDHHC9 and PROC, of which we functionally assessed AGAP1 using a zebrafish model. Our investigations reinforce that CP is a heterogeneous neurodevelopmental disorder with known as well as novel genetic determinants.
Asunto(s)
Cromosomas Humanos X , Enfermedades Genéticas Ligadas al Cromosoma X , Predisposición Genética a la Enfermedad/genética , Discapacidad Intelectual/genética , Mutación/genética , Proteínas/genética , Proteínas Portadoras/metabolismo , Estudios de Casos y Controles , Estudios de Cohortes , Proteínas de Unión al ADN , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Proteínas Nucleares/metabolismo , Fenotipo , ARN Mensajero/metabolismoAsunto(s)
ADN Helicasas , Discapacidad Intelectual/genética , Mutación , Proteínas Nucleares/genética , Alelos , Secuencia de Bases , Mapeo Cromosómico , Cartilla de ADN/genética , Femenino , Ligamiento Genético , Humanos , Masculino , Datos de Secuencia Molecular , Linaje , Síndrome , Cromosoma X/genética , Proteína Nuclear Ligada al Cromosoma X , Talasemia alfa/genéticaAsunto(s)
Discapacidad Intelectual/genética , Proteínas Quinasas/genética , Proteínas Quinasas S6 Ribosómicas 90-kDa , Secuencia de Aminoácidos , Secuencia de Bases , Femenino , Ligamiento Genético , Humanos , Discapacidad Intelectual/enzimología , Masculino , Mutación Missense , Linaje , Polimorfismo Conformacional Retorcido-Simple , Proteínas Quinasas/metabolismo , Cromosoma X/genéticaRESUMEN
Aristaless-related homeobox gene (ARX) is an important paired-type homeobox gene involved in the development of human brain. The ARX gene mutations are a significant contributor to various forms of X-chromosome-linked mental retardation with and without additional features including epilepsy, lissencephaly with abnormal genitalia, hand dystonia or autism. Here we demonstrate that the human ARX protein is a potent transcriptional repressor, which binds to Groucho/transducin-like enhancer of split (TLE) co-factor proteins and the TLE1 in particular through its octapeptide (Engrailed homology repressor domain (eh-1) homology) domain. We show that the transcription repression activity of ARX is modulated by two strong repression domains, one located within the octapeptide domain and the second in the region of the polyalanine tract 4, and one activator domain, the aristaless domain. Importantly, we show that the transcription repression activity of ARX is affected by various naturally occurring mutations. The introduction of the c.98T>C (p.L33P) mutation results in the lack of binding to TLE1 protein and relaxed transcription repression. The introduction of the two most frequent ARX polyalanine tract expansion mutations increases the repression activity in a manner dependent on the number of extra alanines. Interestingly, deletions of alanine residues within polyalanine tracts 1 and 2 show low or no effect. In summary we demonstrate that the ARX protein is a strong transcription repressor, we identify novel ARX interacting proteins (TLE) and offer an explanation of a molecular pathogenesis of some ARX mutations, including the most frequent ARX mutations, the polyalanine tract expansion mutations, c.304ins(GCG)7 and c.428_451dup.
Asunto(s)
Elementos de Facilitación Genéticos/fisiología , Proteínas de Homeodominio/genética , Mutación , Proteínas Represoras/metabolismo , Factores de Transcripción/genética , Transcripción Genética/fisiología , Factores de Edad , Alanina/genética , Animales , Encéfalo/citología , Células Cultivadas , Embrión de Mamíferos , Regulación del Desarrollo de la Expresión Génica/fisiología , Humanos , Inmunoprecipitación/métodos , Hibridación in Situ/métodos , Ratones , Neuronas/metabolismo , Transducina/metabolismo , Transfección/métodosRESUMEN
BACKGROUND: Börjeson-Forssman-Lehmann syndrome (BFLS; MIM 301900) is an infrequently described X linked disorder caused by mutations in PHF6, a novel zinc finger gene of unknown function. OBJECTIVE: To present the results of mutation screening in individuals referred for PHF6 testing and discuss the value of prior X-inactivation testing in the mothers of these individuals. RESULTS: 25 unrelated individuals were screened (24 male, one female). Five PHF6 mutations were detected, two of which (c.940A-->G and c.27_28insA) were novel. One of these new mutations, c.27_28insA, was identified in a female BFLS patient. This was shown to be a de novo mutation arising on the paternal chromosome. This is the first report of a clinically diagnosed BFLS female with a confirmed PHF6 mutation. In addition, the X-inactivation status of the mothers of 19 males with suggested clinical diagnosis of BFLS was determined. Skewed (> or =70%) X-inactivation was present in five mothers, three of whom had sons in whom a PHF6 mutation was detected. The mutation positive female also showed skewing. CONCLUSIONS: The results indicate that the success of PHF6 screening in males suspected of having BFLS is markedly increased if there is a positive family history and/or skewed X-inactivation is found in the mother.
Asunto(s)
Anomalías Múltiples/genética , Proteínas Portadoras/genética , Discapacidad Intelectual/genética , Mutación , Trastornos de los Cromosomas Sexuales/genética , Cartilla de ADN , Femenino , Tamización de Portadores Genéticos , Humanos , Masculino , Proteínas Represoras , Dedos de Zinc/genéticaRESUMEN
Rett syndrome (RS) is a severe neurodevelopmental disorder that contributes significantly to severe intellectual disability in females worldwide. It is caused by mutations in MECP2 in the majority of cases, but a proportion of atypical cases may result from mutations in CDKL5, particularly the early onset seizure variant. The relationship between MECP2 and CDKL5, and whether they cause RS through the same or different mechanisms is unknown, but is worthy of investigation. Mutations in MECP2 appear to give a growth disadvantage to both neuronal and lymphoblast cells, often resulting in skewing of X inactivation that may contribute to the large degree of phenotypic variation. MeCP2 was originally thought to be a global transcriptional repressor, but recent evidence suggests that it may have a role in regulating neuronal activity dependent expression of specific genes such as Hairy2a in Xenopus and Bdnf in mouse and rat.
Asunto(s)
Proteína 2 de Unión a Metil-CpG/genética , Proteínas Serina-Treonina Quinasas/genética , Síndrome de Rett/genética , Animales , Modelos Animales de Enfermedad , Humanos , Mutación , Neuronas/fisiologíaRESUMEN
We have identified a novel gene, FMR3, originating from the FRAXE CpG island. The FMR3 gene is transcribed from the opposite strand to the FMR2 gene. Analogous to the silencing of the FMR1 and FMR2 genes, FMR3 transcription is extinguished by FRAXE full mutation. Although the role of FMR3 in FRAXE associated mild to borderline mental retardation is not yet clear, lack of expression of FMR3 in FRAXE full mutation males means that the FMR3 gene is potentially involved.